ABC Home
Loans
Investments
Insurance
Payments
Download ABCD

Experience finance made simple on the new ABCD app!

Scan to Download the App

Playstore Appstore
1800-270-7000

Aditya Birla Sun Life AMC Limited

Aditya Birla Sun Life AMC Limited

    Our Menu
    Invest with Us
    Metaverse

    Aditya Birla Sun Life AMC Limited

    Subscribe

    Indian Pharma: In the pink of health

    Transcript

    Sep 06, 2024
    5 Mins Read
    Mahesh Patil
    Dhaval Shah

    Listen to Article

    India pharma is flexing muscle, showing little sign of flagging. In the last 12 months, NSE Pharma has returned 50%, comfortably beating the benchmark Nifty that went up by 31% while also returning an average 19% versus Nifty’s 15% in the last 3 years. This is a sharp reversal from the sector’s underperformance in 4 out of the 5 previous years.

    The blocks built and added over the decade prior, are finally falling into place for Indian Pharma. The sector is focussed on two markets: the $24 billion branded generics domestic bazaar, and the $28 billion formulations and API exports, to both developed and developing countries. The domestic market is dominated by Indian companies with the top 10 holding a 44% share. Rising non-communicable disease due to lifestyle changes, rising income levels that improve affordability and competitive pricing (average price hike is 5-7%) - should ensure that the 8-10% annual growth rate will continue for the foreseeable future. On their part, pharma companies have added salesforce, expanded doctor reach, ventured into trade generics and collaborated with multi-national corporations. This has grown the segment’s reach to a wider set of the population while offering best-in-class treatment options.


    India’s $28 billion exports grew by 10% last year and 8% in the last 6 years. India has the highest number of FDA-compliant plants outside of the US, nearly 1,400 WHO-GMP and 253 European Directorate of Quality Medicines (EDQM) approved plants with modern state-of-the-art technology. It is not for nothing that India is called the pharmacy of the world. With the healthcare burden in developed countries straining systems and cramping access, India presents a perfect partner of choice for those seeking quality medicine and intervention at affordable rates. Indian companies have steadily added capacity as well as capability – rolling out a stream of complex and biological products. India’s pharma prowess is buttressed by its abundance of skilled manpower, low labour costs, friendly government policies – SEZ, pharma parks, PLI – uninterrupted electricity and commitment to global ESG best practices.


    In the last decade, the number of Contract Development and Manufacturing Organizations (CDMOs) have mushroomed that have partnered global giants from pre-clinical to post-marketing stage. While Indian companies have stolen a march in generic manufacturing, a lot more needs to be done on R&D front from all stakeholders so that India can move from being a follower to a leader; tighten IP laws that make global giants hesitant to partner on patented drugs; standardize quality across manufacturers.

    What could derail this story? Factors like compliance failures, increase in raw material costs and price competition in developed markets that could hurt profitability and eventually supplies of critical drugs, leading to sector de-rating. NSE Pharma is trading at 47% premium to Nifty, which is higher than the 10-year average of 31% but lower than the 50-90% premium seen during 2014-15. Given the sharp run-up in pharma stocks, domestic branded market offers a viable investment option: the perfect defensive play with huge untapped potential, inelastic demand, lower regulatory requirements, cost arbitrage vs global peers that other countries would find hard to beat. It is prudent to be invested in a sector that has so many natural advantages!

    Source: Bloomberg, ABSLAMC Research

    The views expressed in this article are for knowledge/information purpose only and is not a recommendation, offer or solicitation of business or to buy or sell any securities or to adopt any investment strategy. Aditya Birla Sun Life AMC Limited (“ABSLAMC”) /Aditya Birla Sun Life Mutual Fund (“the Fund”) is not guaranteeing/offering/communicating any indicative yield/returns on investments. The sector(s)/stock(s)/issuer(s) mentioned do not constitute any research report/recommendation of the same and the Fund may or may not have any future position in these sector(s)/stock(s)/issuer(s).


    The article was first published in Financial Express on September 02, 2024


    Mutual Fund investments are subject to market risks, read all scheme related documents carefully.



    Mahesh Patil

    About Author

    Mr. Mahesh Patil is the Chief Investment Officer (CIO) of Aditya Birla Sun Life AMC Limited. As the CIO Mahesh oversees over INR 3 lakh crore of assets under management. With over thirty years of rich experience in fund and investment management, Mahesh leads the entire investment team, comprising fund managers and analysts. He personally manages funds such as Aditya Birla Sun Life Frontline Equity, Aditya Birla Sun Life Multi-Cap Fund, and Aditya Birla Sun Life Focused Equity.

    Mahesh has been with Aditya Birla Sun Life AMC since October 2005. Mahesh was awarded the India CIO of the Year, Equity by Asia Asset Management in 2016 and 2018. He has been awarded Chairman’s Individual Award by The Aditya Birla group for being an Accomplished Leader in 2015.

    He has previously worked at CMC Limited, Tata Economic Consultancy Services, Parag Parikh Financial Advisory Services Limited, Motilal Oswal Securities Limited and at Reliance Infocom Limited.

    He holds a Bachelor’s Degree in Engineering from the University of Bombay and a Master’s degree in Management Studies from University of Bombay. He has also qualified the Chartered Financial Analysts examination from the Institute of Chartered Financial Analysts of India (ICFAI), Hyderabad.

    Read More

    Dhaval Shah

    About Author

    Mr. Dhaval Shah is a Fund Manager and Senior Analyst with Aditya Birla Sun Life AMC Limited (ABSLAMC). He has an overall experience of more than 16 years in Indian equity markets and has been a part of ABSLAMC since 2015.

    Prior to ABSLAMC, Dhaval has worked with Reliance Capital Asset Management Ltd., Morgan Stanley Investment Management and Edelweiss Securities Ltd.

    Dhaval is an MBA in Finance from Mumbai University. He is also a CFA Charter Holder.

    Read More

    You May Also Like